Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J's Symtuza Will Debut In Europe On Cramped HIV Market

Executive Summary

Johnson & Johnson's combination HIV therapy Symtuza has secured a greenlight in Europe, marking its first approval worldwide – but will the big pharma be able to catch up with successful HIV opponents from AbbVie and Gilead?

You may also be interested in...



J&J’s Symtuza Approved, But Commercial Outlook Uncertain

The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.

How Will Novel Agents Impact The HIV Market?

ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research. 

Janssen's Darunavir-Based Single-Tablet Effective In Late-Stage Switching Study

Switching to a once-daily single tablet containing four constituents that is centered on Janssen's protease inhibitor darunavir was non-inferior to other combination therapies after 48 weeks of therapy, say researchers running the Phase III EMERALD study.

Topics

Related Companies

UsernamePublicRestriction

Register

SC099192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel